Risk factors predicting graft-versus-host disease and relapse-free survival after allogeneic hematopoietic stem cell transplantation in relapsed or refractory non-Hodgkin’s lymphoma-Reference-Cited by-同舟云学术

Risk factors predicting graft-versus-host disease and relapse-free survival after allogeneic hematopoietic stem cell transplantation in relapsed or refractory non-Hodgkin’s lymphoma

Published:2019-05-14 Issue:7 Volume:98 Page:1743-1753
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Jeon Young-Woo,Yoon Seugyun,Min Gi June,Park Sung-Soo,Park Silvia,Yoon Jae-Ho,Lee Sung-Eun,Cho Byung-Sik,Eom Ki-Seong,Kim Yoo-Jin,Kim Hee-Je,Lee Seok,Min Chang-Ki,Lee Jong Wook,Cho Seok-Goo^ORCID

Funder

National Foundation of Korea

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-019-03714-x.pdf

Reference30 articles.

1. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, Reiser M, Metzner B, Harder H, Hegewisch-Becker S, Fischer T, Kropff M, Reis HE, Freund M, Wormann B, Fuchs R, Planker M, Schimke J, Eimermacher H, Trumper L, Aldaoud A, Parwaresch R, Unterhalt M (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106(12):3725–3732. https://doi.org/10.1182/blood-2005-01-0016

2. Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, Lopez-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N, MabThera International Trial G (2011) CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 12 (11):1013–1022. doi: https://doi.org/10.1016/S1470-2045(11)70235-2

3. Tsai T, Goodman S, Saez R, Schiller G, Adkins D, Callander N, Wolff S, Freytes CO (1997) Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation. Bone Marrow Transplant 20(10):859–863. https://doi.org/10.1038/sj.bmt.1700989